<DOC>
	<DOCNO>NCT02321319</DOCNO>
	<brief_summary>This pediatric study design provide safety information , dose guideline , pharmacokinetic ( PK ) evaluation once-daily hydromorphone hydrochloride ( HCl ) extended-release ( ER ) tablets child chronic painful condition `` opioid-tolerant '' prior enrollment Pediatric Research Equity Act ( PREA ) 2003 .</brief_summary>
	<brief_title>Open-Label Safety PK Study ER Hydromorphone Tablets Opioid-Tolerant Pediatric Chronic Pain Patients</brief_title>
	<detailed_description />
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Hydromorphone</mesh_term>
	<criteria>Inclusion : 1 . Male female subject age 7 17 year . 2 . Chronic cancer noncancer pain ( require aroundtheclock opioid treatment ) currently manage stable dose oral injectable opioid correspond least 6 mg hydromorphone per day least 5 day prior first dose . 3 . Female subject child bear potential must negative serum pregnancy test result Screening Day 1 . If sexually active must surgically sterilize least 12 month prior Screening use contraception least 30 day prior Screening duration study participation least 30 day last dose study drug . 4 . Male subject , reproductive potential , sexually active must agree use acceptable method contraception duration study . 5 . Opioidtolerant . 6 . Subjects must establish favorable response opioid therapy reduce pain . 7 . Subjects must require minimum dose 4 mg ( 1 JURNISTA tablet ) maximum dose 16 mg ( 1 EXALGO tablet ) determine 66 % convert dose hydromorphone HCl per day establish conversion table . 8 . Able swallow whole tablet without break , crush , chew dissolve . 9 . Expected require extend opioid treatment least 1 week . 10 . Subjects must able communicate effectively study personnel . 11 . Subjects parents/legal guardian must able willing follow protocol requirement study restriction . Exclusion : 1 . Life expectancy le 4 week . 2 . History allergy significant intolerance opioid treatment allergy sulfites . 3 . Currently use opioid ( transcutaneous ) analgesic patch . 4 . History drug alcohol dependence . 5 . History renal , hepatic , cardiovascular , respiratory condition would contraindicate participation study . 6 . Plan undergo surgical procedure within 3 day Day 1 duration subject participation study . Subjects undergo minor surgical procedure ( eg , central line insertion , biopsy ) eligible participation study . 7 . Exhibit hemodynamic instability . 8 . Have dysphagia , difficulty swallow whole tablet . 9 . Narrowing digestive tract , Short gut syndrome , inflammatory bowel disease , peritonitis , cystic fibrosis , Meckel 's diverticulum , past GI surgery . 10 . Hypothyroidism , Addison 's disease , asthma ( include exercise induce asthma ) require daily inhaler , enlarge prostate , epilepsy , low blood pressure , seizure disorder , high intracranial brain pressure , gallbladder problem , pancreatic disease , liver disease , kidney disease . 11 . Ileostomy paralytic ileus . 12 . Bloodproduct transfusion within 2 week enrollment expect require transfusion study . 13 . Participated study investigational drug device past 30 day prior screen . 14 . Known history human immunodeficiency virus ( HIV ) , hepatitis C virus ( HCV ) hepatitis B virus .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>chronic pain</keyword>
	<keyword>pediatric</keyword>
</DOC>